Surprisingly, it had nothing to do with the pharma company's earnings report.
News & Analysis: Zogenix
One of these stocks continued to see fallout from recent executive moves.
The biotech is making an acquisition deal that investors don't appear to approve of.
ZGNX earnings call for the period ending June 30, 2019.
The company rebounded after remedying an embarrassing regulatory gaffe.
The company cleared up an issue with the FDA.
ZGNX earnings call for the period ending March 31, 2019.
The pharma company got a rejection letter from the U.S. Food and Drug Administration.
Novartis completed its spin-off of eye care specialist Alcon and Zogenix had a drug application rejected.
The FDA refused to accept the biotech's experimental epilepsy medication for review.